Ainos (AIMD) Issues Mid-Year Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Ainos Issues Mid-Year Update: Reaching Strategic Inflection in SmellTech and Immunotherapy
June 16, 2025 8:01 AM EDTAI Nose Platform Advances Toward Scaled Pilot Programs Across Healthcare, Robotics, and Industrials
VELDONA® Oral Interferon Receives Approval to Begin Human Trials in Taiwan
SAN DIEGO, CA / ACCESS Newswire / June 16, 2025 / Ainos, Inc. (NASDAQ: AIMD)(NASDAQ: AIMDW) ("Ainos" or the "Company") today issued a mid-year update outlining key strategic milestones achieved during the first half of 2025. The Company has transitioned from R&D to commercial execution, marked by its first AI Nose-driven... More
